BioReactions: Cell Culture Services
This division of Bioprocessing, Inc. begun in 2000, is specialized in the in vitro production of proteins and antibodies from human, mammalian, bacterial and hybridoma cell lines. We draw from our 14+ years of tumor marker cell culture production and purification experience to offer our highly specialized expertise to companies who need oncology related assay reagents. Our contract reagent manufacturing is performed using GMP and our company is ISO 9001:2000 certified. Our production technology for the growth of cell-cultured products is focused on using a continuous perfusion bioreactor system, Celligen Plus. Our technology for the purification of cell culture products (i.e. secreted and r-proteins, monoclonal antibodies) utilizes our antibody and large molecule glycoprotein experiences. For antibodies hypercell, and either protein G or A are routinely used. For proteins a variety of MEP methods are employed including affinity, ion exchange, and size exclusion chromatographies.
Our experienced scientists work directly with your scientists with complete confidentiality to custom produce your reagents. Our small but expert staff is highly responsive to your time sensitive projects.
Because of our focused long-term experience and direct supplier relationships with large diagnostic companies in the tumor marker immunoassay clinical market we are a practical choice for biotech or pharma companies who need biomarker reagents for oncology related drug therapy programs. We may be involved at any stage of the drug development cycle but manufacturing immunology based reagents before or during Phase 1 using GMP manufactured assay reagents is a cost effective way to begin the transition of immunoassay based biomarkers assays from a GLP environment to a GMP environment. This strategy enables the drug developer to use critical assay components which are manufactured according to GMP compliance and documentation cost effectively. For example, if a biomarker proves to be useful by helping to improve a drugs efficacy or safety, then the groundwork is complete with respect to raw materials for transition of a biomarker assay from pharma to an FDA approved clinical product. However, if a biomarker sometime during the clinical trials fails to meet the required effectiveness objectives then part of the risk related to cost of assay development (those related to critical component raw materials) has been minimized.
Hybridoma Services
Immunization and Subcloning Services
- Immunization with serum screening
- Immunization without screening
- Subcloning of Hybridomas with screening
Cell Line Preparation and Storage Services
- Cryopreservation
- Storage of Cryopreserved Cell lines
- Preparation of Master Cell Bank
- Preparation of Working Cell Bank
Bioreactor Services/In Vitro Cell Culture Production
Our Strengths Include
- Commitment
- We continuously provide our clients the most efficient technologies and the resources to do a specialized job
- Communication
- From our administrative and technical staff you have immediate access to key personnel; we are both diligent and strident about this aspect of our client relationships
- Consulting
- We have experience and specific know how which will help you with the production of these oncology related reagents
- Confidentiality
- Bioprocessing Inc. maintains strict confidentiality in all service client business. Most discussions of our services begin with confidentiality agreements to fully protect the client. All developed and produced cell lines are the sole property of the client.
- Quality system
- Products are manufactured in tune and in step with the regulatory requirements for the clinical lab market. Excellent documentation and strict adherence to standard operating procedures is a priority
- Efficiency
- Our small size is an advantage. We can implement projects quickly using state of the art technologies
You may also download the full catalog in PDF format.